Corbus Pharmaceuticals Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Corbus Pharmaceuticals Holdings yıllık ortalama 18.5% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 7.7% annual. Gelirler azalıyor .

Anahtar bilgiler

18.5%

Kazanç büyüme oranı

35.9%

EPS büyüme oranı

Biotechs Sektör Büyümesi	-14.6%
Gelir büyüme oranı	-85.2%
Özkaynak getirisi	-27.9%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Corbus Pharmaceuticals Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:3371 Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	0	-35	14
31 Mar 24	0	-34	14
31 Dec 23	0	-45	14
30 Sep 23	0	-47	15
30 Jun 23	0	-46	16
31 Mar 23	0	-51	17
31 Dec 22	0	-42	19
30 Sep 22	0	-42	18
30 Jun 22	0	-35	20
31 Mar 22	0	-39	20
31 Dec 21	1	-46	20
30 Sep 21	2	-44	22
30 Jun 21	3	-77	24
31 Mar 21	3	-98	26
31 Dec 20	4	-111	28
30 Sep 20	6	-129	29
30 Jun 20	7	-115	27
31 Mar 20	36	-75	25
31 Dec 19	36	-71	24
30 Sep 19	35	-62	21
30 Jun 19	34	-56	19
31 Mar 19	6	-70	17
31 Dec 18	5	-56	13
30 Sep 18	3	-49	12
30 Jun 18	3	-41	11
31 Mar 18	2	-37	10
31 Dec 17	2	-32	9
30 Sep 17	3	-29	9
30 Jun 17	3	-28	9
31 Mar 17	3	-25	8
31 Dec 16	2	-20	6
30 Sep 16	2	-15	5
30 Jun 16	1	-12	4
31 Mar 16	1	-10	4
31 Dec 15	1	-9	4
30 Sep 15	0	-8	3
30 Jun 15	0	-6	3
31 Mar 15	0	-4	2
31 Dec 14	0	-3	1
30 Sep 14	0	-2	1
30 Jun 14	0	-1	1
31 Mar 14	0	-1	0

Kaliteli Kazançlar: 3371 şu anda kârlı değil.

Büyüyen Kar Marjı: 3371 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 3371 kârlı değildir, ancak son 5 yılda zararlarını yılda 18.5% oranında azaltmıştır.

Büyüme Hızlandırma: 3371 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 3371 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -20.8% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 3371 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -27.86% ) sahiptir.

Corbus Pharmaceuticals Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2022 earnings released: US$0.18 loss per share (vs US$0.28 loss in 1H 2021)

First quarter 2022 earnings released: US$0.075 loss per share (vs US$0.14 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.017 loss per share (vs US$0.43 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.52 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.43 loss in 1Q 2020)

Recent updates

Corbus Pharmaceuticals Holdings, Inc. Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Negative shareholders equity

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering.

Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 (SYS6002)

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)

Corbus Pharmaceuticals Holdings, Inc. Presents Results of Two Pre-Clinical Studies on its Anti-VETA>8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. Appoints Anne Altmeyer to Board of Directors

First half 2022 earnings released: US$0.18 loss per share (vs US$0.28 loss in 1H 2021)

Corbus Pharmaceuticals Holdings Gets a 180-Day Extension to January 2, 2023, to Regain Compliance with the Minimum Bid Price Requirement

Corbus Pharmaceuticals Holdings, Inc. Enters into a Binding Term Sheet with Venn Therapeutics, LLC, to Resolve the Claims by Venn Against the Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Announces That New Preclinical Data for CRB-601 Are Being Presented in an Oral Presentation At the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference in New York

First quarter 2022 earnings released: US$0.075 loss per share (vs US$0.14 loss in 1Q 2021)

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 18, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Corbus Pharmaceuticals Holdings Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Third quarter 2021 earnings released: US$0.017 loss per share (vs US$0.43 loss in 3Q 2020)

Head of Research & Chief Medical Officer Barbara White has left the company

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.52 loss in 2Q 2020)

Corbus Pharmaceuticals Holdings, Inc.(NasdaqGM:CRBP) dropped from Russell 3000E Growth Index

Corbus Pharmaceuticals Announces Topline Results from Determine Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Corbus Pharmaceuticals Holdings, Inc. Announces Licensing Deals for Two New Monoclonal Antibodies, CRB-601 and CRB-602 to Further Expand Pipeline into Cancer and Fibrotic Diseases

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.43 loss in 1Q 2020)

Full year 2020 earnings released: US$1.42 loss per share (vs US$1.12 loss in FY 2019)

Corbus Pharmaceuticals Holdings, Inc. Provides Clinical Program Updates

Corbus Pharmaceuticals Holdings, Inc. to Report Q4, 2020 Results on Mar 15, 2021

New 90-day high: €1.87

New 90-day high: €1.25

Corbus Pharmaceuticals Holdings, Inc. Announces the Resignation of Robert Discordia as Chief Operating Officer

Corbus Pharmaceuticals Holdings, Inc. Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Robert Discordia Will No Longer Serve as Chief Operating Officer of Corbus Pharmaceuticals Holdings, Inc

New 90-day low: €1.01

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

New 90-day high - €7.81

Corbus Pharmaceuticals Holdings, Inc. to Report Q2, 2020 Results on Aug 06, 2020

New 90-day low - €5.38

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin